{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:08:49Z","timestamp":1791576529929,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Blueprint Medicines Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198) and Phase 2 PATHFINDER (NCT03580655) trials (<jats:italic>N<\/jats:italic>\u2009=\u2009176) and patients treated with best available therapy (BAT; <jats:italic>N<\/jats:italic>\u2009=\u2009141). A multi-center, observational, retrospective chart review study was conducted at six study sites (four European, two American) to collect data from patients with AdvSM who received BAT; these data were pooled with data from EXPLORER and PATHFINDER. Comparisons between outcomes of OS, duration of treatment (DOT), and maximum reduction in serum tryptase were conducted between the treatment cohorts, with adjustment for key covariates. The results indicated that the avapritinib cohort had significantly better survival (adjusted hazard ratio (HR) (95% confidence interval (CI)): 0.48 (0.29, 0.79); <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and significantly longer DOT (HR: 0.36 (0.26, 0.51); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared to the BAT cohort. Additionally, the mean difference in percentage maximum reduction in serum tryptase levels was 60.3% greater in the avapritinib cohort (95% CI: \u221272.8, \u221247.9; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). With no randomized controlled trials comparing avapritinib to BAT, these data offer crucial insights into the improved efficacy of avapritinib for the treatment of AdvSM.<\/jats:p>","DOI":"10.1038\/s41375-022-01615-z","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T07:03:01Z","timestamp":1657004581000},"page":"2108-2120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-6507","authenticated-orcid":false,"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1504","authenticated-orcid":false,"given":"Johannes","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka J.","family":"Bobbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Norregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Dimitrijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Louie-Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene A.","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sriskandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvam R.","family":"Sendhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325.","journal-title":"Leuk Res"},{"key":"1615_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, F\u00f6dinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435\u201353.","journal-title":"Eur J Clin Invest"},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420\u20137.","journal-title":"Blood."},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5:e646.","journal-title":"HemaSphere"},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.26118","volume":"96","author":"A Pardanani","year":"2021","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol. 2021;96:508\u201325.","journal-title":"Am J Hematol"},{"key":"1615_CR6","unstructured":"Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th ed.). Lyon, France: IARC; 2017."},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"K-H Lim","year":"2009","unstructured":"Lim K-H, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727\u201336.","journal-title":"Blood."},{"key":"1615_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","volume":"121","author":"S Georgin-Lavialle","year":"2013","unstructured":"Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris M-O, Hermine O, Damaj G. Mast cell leukemia. Blood. 2013;121:1285\u201395.","journal-title":"Blood."},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530\u201341.","journal-title":"N Engl J Med"},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","volume":"102","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny H-P, Sotlar K, et al. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017;102:1035\u201343.","journal-title":"Haematologica."},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/thno.51872","volume":"11","author":"HC Kluin-Nelemans","year":"2021","unstructured":"Kluin-Nelemans HC, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, et al. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics. 2021;11:292.","journal-title":"Theranostics."},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2019000932","volume":"135","author":"A Reiter","year":"2020","unstructured":"Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135:1365\u201376.","journal-title":"Blood."},{"key":"1615_CR13","doi-asserted-by":"publisher","unstructured":"L\u00fcbke J, Schwaab J, Naumann N, Horny H-P, Wei\u00df C, Metzgeroth G, et al. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis. J Clin Oncol. 2022:JCO2101849. https:\/\/doi.org\/10.1200\/JCO.21.01849.","DOI":"10.1200\/JCO.21.01849"},{"key":"1615_CR14","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.19.00640","volume":"37","author":"M Jawhar","year":"2019","unstructured":"Jawhar M, Schwaab J, \u00c1lvarez-Twose I, Shoumariyeh K, Naumann N, L\u00fcbke J, et al. MARS: mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37:2846\u201356.","journal-title":"J Clin Oncol"},{"key":"1615_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32:470\u20138.","journal-title":"Leukemia."},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","volume":"130","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130:137\u201345.","journal-title":"Blood."},{"key":"1615_CR17","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1056\/NEJMc1515403","volume":"374","author":"M-O Chandesris","year":"2016","unstructured":"Chandesris M-O, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, et al. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2605\u20137.","journal-title":"N Engl J Med"},{"key":"1615_CR18","doi-asserted-by":"publisher","unstructured":"Singh A, Al\u2010Kali A, Begna KH, Litzow MR, Larsen JT, Sher T, et al. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022. https:\/\/doi.org\/10.1002\/ajh.26498.","DOI":"10.1002\/ajh.26498"},{"key":"1615_CR19","doi-asserted-by":"publisher","first-page":"68950","DOI":"10.18632\/oncotarget.10711","volume":"8","author":"I Alvarez-Twose","year":"2016","unstructured":"Alvarez-Twose I, Matito A, Morgado JM, S\u00e1nchez-Mu\u00f1oz L, Jara-Acevedo M, Garc\u00eda-Montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2016;8:68950\u201363.","journal-title":"Oncotarget."},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","volume":"126","author":"S Barete","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126:1009\u201316.","journal-title":"Blood."},{"key":"1615_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/bjh.17932","volume":"196","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Kittur J, Farrukh F, Begna KH, Patnaik MM, Al-Kali A, et al. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol. 2022;196:975\u201383.","journal-title":"Br J Haematol"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.21561","volume":"84","author":"KH Lim","year":"2009","unstructured":"Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon\u2010alpha, hydroxyurea, imatinib mesylate or 2\u2010chlorodeoxyadenosine. Am J Hematol. 2009;84:790\u20134.","journal-title":"Am J Hematol"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van\u2019t Wout JW, Verhoef G, Gerrits WB, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270\u20136.","journal-title":"Blood."},{"key":"1615_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","volume":"28","author":"AW Hauswirth","year":"2004","unstructured":"Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28:249\u201357.","journal-title":"Leuk Res"},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264\u201374.","journal-title":"J Clin Oncol"},{"key":"1615_CR26","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27:2183\u201391.","journal-title":"Nat Med"},{"key":"1615_CR27","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27:2192\u20139.","journal-title":"Nat Med"},{"key":"1615_CR28","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/leu.2016.190","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016;30:2342\u201350.","journal-title":"Leukemia."},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","volume":"30","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis. Leukemia. 2016;30:136\u201343.","journal-title":"Leukemia."},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Elberink JNO, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): A retrospective cohort study. Lancet Haematol. 2019;6:e638\u20139.","journal-title":"Lancet Haematol"},{"key":"1615_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/00224065.1969.11980344","volume":"1","author":"W Nelson","year":"1969","unstructured":"Nelson W. Hazard plotting for incomplete failure data. J Qual Technol. 1969;1:27\u201352.","journal-title":"J Qual Technol"},{"key":"1615_CR32","first-page":"701","volume":"6","author":"O Aalen","year":"1978","unstructured":"Aalen O. Nonparametric inference for a family of counting processes. Ann Stat. 1978;6:701\u201326.","journal-title":"Ann Stat"},{"key":"1615_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk MJ, Westreich D, Wiesen C, Sturmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173:761\u20137.","journal-title":"Am J Epidemiol"},{"key":"1615_CR34","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379.","journal-title":"Stat Med"},{"key":"1615_CR35","doi-asserted-by":"publisher","unstructured":"Pilkington H, Smith S, Roskell N, Iannazzo S. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis. Future Oncol. 2022. https:\/\/doi.org\/10.2217\/fon-2021-1509.","DOI":"10.2217\/fon-2021-1509"},{"key":"1615_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","volume":"115","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lim K-H, Lasho TL, Finke CM, McClure RF, Li C-Y, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150\u20131.","journal-title":"Blood."},{"key":"1615_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01615-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:10:12Z","timestamp":1659337812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01615-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01615-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AR, JG, I\u00c1-T, DHR, JL, JS, IAG, CP, WRS, PS, PV, and DJD are affiliated with institutions that have received consulting fees for this study from Blueprint Medicines Corporation. CN, SD, ES, and ML-G are employees of Blueprint Medicines Corporation and hold stock\/options. PJB, AW, AC, SRS, and MSD are employees of Analysis Group, Inc., which has received consulting fees from Blueprint Medicines Corporation for the conduct of this research. AR was a member of the Study Steering Committee for the global trial of midostaurin (Novartis), the RAC for studies of avapritinib in AdvSM (Blueprint Medicines Corporation), and the Study Steering Committee for the phase II trial of ripretinib in AdvSM (Deciphera Pharmaceuticals); has received research funding for the conduct of these trials; and has received honoraria and reimbursement of travel expenses from Novartis, Blueprint Medicines Corporation, and Deciphera Pharmaceuticals. JG has received consulting fees and research funding from Blueprint Medicines Corporation, Deciphera, Incyte and Kartos Therapeutics, and has served as chair of the RAC for Blueprint Medicines Corporation\u2019 EXPLORER study, and for the PATHFINDER study, and as co-chair for the Deciphera Study Steering Committee for ripretinib in AdvSM, and chair of the Central Response Review Committee for the phase 2 study of bezuclastinib in AdvSM. I\u00c1-T is the principal investigator of the PATHFINDER study in Spain and has received advisory board fees from Blueprint Medicines Corporation; and has participated in educational events for Novartis. DHR has received consulting fees and research funding from Blueprint Medicines Corporation, is a member of the RACs for the EXPLORER and PATHFINDER studies, and has received honoraria from Novartis for educational events and consultancy. JS has received advisory board fees from Blueprint Medicines Corporation and Novartis. PV has received honoraria from AOP Orphan Pharmaceuticals, Blueprint Medicines Corporation, Celgene, Novartis, and Pfizer. DJD has served as a consultant for Amgen, Agios, Autolus, Blueprint Medicines Corporation, Forty-Seven, Incyte Corporation, Jazz, Novartis, Pfizer, Shire and Takeda, and received research funding from AbbVie, Blueprint Medicines Corporation, GlycoMimetics and Novartis. JL, IAG, CP, WRS, and PS have no further competing interests to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}